Pharmaceutical foreign direct investment is likely to focus on more advanced and faster-growing markets in the region, such as Brazil and Mexico. Poor intellectual property regulation is a major deterrent to investment and new drug launches. ...Poor intellectual property regulation is a major deterrent to investment and new drug launches. The absence of any comprehensive pricing or reimbursement system leaves multinationals in a weak position against low-cost competitors. Patented medicines are not stocked by public-sector pharmacies. ...Test data exclusivity stipulated by the EU Free Trade Agreement (FTA) may dampen growth in generic drugs. Government failure to contain disease transmission and prevent environmental devastation from oil spills is negatively impacting public health.
...Market conditions for foreign players, as well as importers, should improve as a result of various FTAs. Government support for the generic drugs industry and improvement of regulation should benefit bioequivalent generic drugs manufacturers over the longer term. ...Market conditions for foreign players, as well as importers, should improve as a result of various FTAs. Government support for the generic drugs industry and improvement of regulation should benefit bioequivalent generic drugs manufacturers over the longer term. Foreign retail chains entry should improve supply chains and reduce the presence of unregistered and fake medicines. ...Improvements in price transparency may accelerate generic drugs market growth. Relaxation of biosimilar regulations could provide a welcome boost to Peru s research sector.
...In August ----, the high court of Peru ruled that the health ministry must distribute the morning-after emergency contraception pill at public healthcare clinics across the country, overturning a ---- court decision. The previous ruling allowed the pill to be distributed at private pharmacies but not public hospitals due to doubts over the drug s efficacy. ...
